法国赛诺菲药厂将协助强生生产新冠疫苗 月产约1,200万剂
法国赛诺菲(Sanofi)药厂表示,将协助强生(Johnson & Johnson)(JNJ.US)生产新冠苗。公司表示,在获得授权後,赛诺菲将在法国Marcy l’Etoile疫苗生产,每月生产约1,200万剂。公司早前已与辉瑞(Pfizer)(PFE.US)及BioNTech协议,提供协助以生产逾1.25亿剂新冠疫苗。
另外,赛诺菲及葛兰素史克重启新冠疫苗测试,他们更改疫苗组成,以增强疫苗为50岁以上人士的免疫能力,预计第二季进入最後阶段临床测试,并能在年底供应疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.